Resources

Multi-indication drugs open new possibilities for pharmaceutical marketing but also bring unique challenges. Approved for multiple conditions, these treatments require a targeted, data-driven strategy to unlock their full potential across diverse therapeutic areas. In Japan, traditional sales and distribution data...

Drawing from recent conversations with Australian healthcare innovators, including discussions at AusBiotech 2024, Dr. Peter Cronin explores the evolving challenges of US market entry. He shares insights on how companies are moving beyond traditional approaches to embrace data-driven, patient-centric strategies...

The ability to see and act on facility-level insights is not just an advantage – it's a necessity. With Prospection AI and Facility Insights, pharmaceutical companies are equipped to treat patients with greater precision and confidence, driving both business success...

Patient-centric intelligence (PCI) offers Australian biotech and medical device companies a powerful tool for navigating the US healthcare market. Discover how PCI can unlock market potential, mitigate risks, and strengthen pitches to partners and investors.

Learn how Patient-Centric Intelligence (PCI) platforms can enhance collaborative brand management in the pharmaceutical industry. By integrating data and fostering cross-functional teamwork, PCI platforms empower teams to make informed decisions that improve patient outcomes and optimise brand performance. Discover how...

Generic analytics tools often fail to address the complexity of patient data in pharma. Learn why putting specialized intelligence platforms in the hands of analytics as well as commercial teams is essential for generating actionable insights that drive better patient...

Bruce Goodwin, former President of Janssen Japan and Managing Director of Janssen ANZ as well as Prospection Board member, shares his reflections and key takeaways from moderating Prospection's Pharma Executive Roundtable on AI and Generative AI in Tokyo. Get Bruce's...

RWD alone isn't enough. To truly understand patients and drive meaningful improvements, you need PCI. Find out why RWD falls short and how PCI bridges the gap, providing pharmaceutical companies with the insights they need.

Mr. Eiichi Naka, a senior pharma leader with 40 years experience, discusses patient-centric PSPs and the impact of AI in driving outcomes in rare disease.